Vulcan Ventures, Inc.
Michael Kranda has been a member of PTC's board of directors since December 2003. Mr. Kranda is currently CEO, President and director of Anesiva, a publically traded biotech company in South San Francisco, CA. Prior to joining Anesiva, Mr. Kranda led life science venture investments as managing director for Vulcan Capital, and continues to serve as a consultant. From July 1996 to July 2002, Mr. Kranda served as Chief Executive Officer at Oxford GlycoSciences, a publically traded biotechnology company headquartered in London. Prior to joining Oxford GlycoSciences, Mr. Kranda was President and Chief Operating Officer at Immunex Corporation (now Amgen). Mr. Kranda received his B.A. and M.B.A from University of Washington School of Business.